Clinical trial · Interventional
Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Carboplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
NCT00295789CI-TRIAL-00023992completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the clinical benefits of Paclitaxel plus Carboplatin compared with Paclitaxel plus Cisplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy: Paclitaxel/Carboplatin | Drug | — | UNRESOLVED |
| chemotherapy: Paclitaxel/Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Drug: chemotherapy: Paclitaxel/Cisplatin
- interventionNames
- Drug: chemotherapy: Paclitaxel/Cisplatin
- type
- EXPERIMENTAL
- label
- 2
- description
- Drug: chemotherapy: Paclitaxel/Carboplatin
- interventionNames
- Drug: chemotherapy: Paclitaxel/Carboplatin
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- During the study conduct
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. histologically proven uterine cervical cancer 2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix 3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or persistent cervical cancer after curative first line treatments, 3)the second relapse or persistent cervical cancer after curative second line treatments including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse 4. Patients may have been previously treated with less than 50 Gy of palliative radiation therapy 5. Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiation therapy 6. one of the followings, 1)There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity, and some of them have been irradiated 7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity 8. no bilateral hydronephrosis 9. no prior chemotherapy including more than two platinum-containing regimens 10. no prior chemotherapy including taxane 11. age: 20 to75 years 12. PS: 0-2 13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT(AST)≦100IU/l, sCre ≦1.2 mg/dl, Ccr≧50ml/min in using the Cockcroft-Gault equation, and normal ECG 14. written informed consent Exclusion Criteria: 1. patients who have some neurologically functional disorder 2. symptomatic CNS metastasis 3. hypersensitive to alcohol 4. active infection 5. HBs antigen positive 6. uncontrollable hypertension 7. history of myocardiac infarction within six months 8. unstable angina 9. uncontrollable diabetes 10. Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years 11. women during pregnancy or breast-feeding 12. patients with psychiatric illness 13. patients who have been treated with the systemic steroids medication
References
Publications (1)
- DERIVEDKitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35. doi: 10.1200/JCO.2014.58.4391. Epub 2015 Mar 2. PMID 25732161